上皮中性粒細胞激活肽78(ENA78)真核蛋白
Eukaryotic Epithelial Neutrophil Activating Peptide 78 (ENA78)
CXCL5; SCYB5; Chemokine C-X-C-Motif Ligand 5; Small Inducible Cytokine Subfamily B(Cys-X-Cys),Member 5; Neutrophil-activating peptide ENA-78
- 編號EPA860Mu61
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 來源真核表達
- 宿主293F cell
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預(yù)測分子量11.5kDa
- 實際分子量10&14&15kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Ala41~Gln132 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點10.1
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1128¥ 2820¥ 5640¥ 16920¥ 42300
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure . Gene Sequencing (extract)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in ddH2O to a concentration of 0.1-0.2 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA860Mu02 | 上皮中性粒細胞激活肽78(ENA78)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA860Mu02 | 上皮中性粒細胞激活肽78(ENA78)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA860Mu61 | 上皮中性粒細胞激活肽78(ENA78)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA860Mu63 | 上皮中性粒細胞激活肽78(ENA78)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA860Mu61 | 上皮中性粒細胞激活肽78(ENA78)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA860Mu01 | 上皮中性粒細胞激活肽78(ENA78)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA860Mu02 | 上皮中性粒細胞激活肽78(ENA78)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA860Mu01 | 上皮中性粒細胞激活肽78(ENA78)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA860Mu81 | 上皮中性粒細胞激活肽78(ENA78)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAA860Mu71 | 上皮中性粒細胞激活肽78(ENA78)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA860Mu | 上皮中性粒細胞激活肽78(ENA78)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA860Mu | 抗上皮中性粒細胞激活肽78抗體(Anti-ENA78)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| SCA860Mu | 上皮中性粒細胞激活肽78(ENA78)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA860Mu | 上皮中性粒細胞激活肽78(ENA78)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA860Mu01 | 上皮中性粒細胞激活肽78(ENA78)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
| 雜志 | 參考文獻 |
| Journal of Biochemical and Molecular Toxicology | Ameliorative Effects of Curcumin on Fibrinogen-Like Protein-2 Gene Expression, Some Oxido-Inflammatory and Apoptotic Markers in a Rat Model of l-Arginine-Induced Acute Pancreatitis.[Pubmed:26862043] |
| Journal of Biochemical and Molecular Toxicology | Ameliorative Effects of Curcumin on Fibrinogen-Like Protein-2 Gene Expression, Some Oxido-Inflammatory and Apoptotic Markers in a Rat Model of l-Arginine-Induced Acute Pancreatitis[pubmed:26862043] |
| OncoTargets and Therapy | The clinical significance of CXCL5 in non-small cell lung cancer.[pubmed:29200871] |
| Biochimie | Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of β-catenin pathway[Pubmed:29471001] |
| Cancer?Biology?&?Therapy | Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38?…[Pubmed: 30404567] |
| Respiratory?Research | Phospholipase Cε plays a crucial role in neutrophilic inflammation accompanying acute lung injury through augmentation of CXC chemokine production from?…[Pubmed: 30634975] |
| American Journal of Pathology | Interleukin17–CXCR2 axis facilitates breast cancer progression by up-regulating neutrophil recruitment[Pubmed: 31654638] |
| Bioactive Materials | Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy[34820587] |
| Am J Cancer Res | Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma[Pubmed:35141005] |